DrugPatentWatch Database Preview

Details for Patent: 10,039,757

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,039,757 protect, and when does it expire?

Patent 10,039,757 protects CABOMETYX and is included in one NDA.

This patent has thirty-eight patent family members in sixteen countries.

Summary for Patent: 10,039,757

Title:	C-Met modulator pharmaceutical compositions
Abstract:	Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed. ##STR00001##
Inventor(s):	Wilson; Jo Ann (San Francisco, CA), Shah; Khalid (Half Moon Bay, CA)
Assignee:	Exelixis, Inc. (Alameda, CA)
Application Number:	15/426,804
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,039,757
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,039,757

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No						TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No						TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-003	Apr 25, 2016		RX	Yes	Yes						TREATMENT OF ADVANCED RENAL CELL CARCINOMA

International Family Members for US Patent 10,039,757

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	082252
Australia	2011278950
Australia	2016247044
Australia	2018220045
Australia	2020203645
Brazil	112013000980
Canada	2805645